Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. - Wikidata - awgldk - TriplyDB

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.

http://www.wikidata.org/entity/Q35758280

about

Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase–dependent DC functions and regulates experimental graft-versus-host disease in mice Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha Targeted disruption of Ing2 results in defective spermatogenesis and development of soft-tissue sarcomas Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Epigenetics of cervical cancer. An overview and therapeutic perspectives Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future Potential use of histone deacetylase inhibitors in cancer therapy Epigenetic treatment of solid tumours: a review of clinical trials Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas Alpha-1-antitrypsin deficiency Medical management of metastatic medullary thyroid cancer Targeted therapy in advanced bladder cancer: what have we learned?Bioactive heterocycles containing endocyclic N-hydroxy groups Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors.Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies Biodegradable thermosensitive hydrogel for SAHA and DDP delivery: therapeutic effects on oral squamous cell carcinoma xenografts Vorinostat induces apoptosis and differentiation in myeloid malignancies: genetic and molecular mechanisms Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma.Synergistic Anticancer Effects of Vorinostat and Epigallocatechin-3-Gallate against HuCC-T1 Human Cholangiocarcinoma Cells.Comparative modeling and benchmarking data sets for human histone deacetylases and sirtuin families.DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.Clinical Toxicities of Histone Deacetylase Inhibitors.Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and β-cell protection Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation.Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.Limited proteolysis of human histone deacetylase 1 Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma.Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer.Vorinostat in solid and hematologic malignancies Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat.Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.

P2860

Q24288997-32D47399-8855-403F-9AF4-266429E3B862 Q24308024-3467A0D7-050D-4CC0-835A-353DC94A78AC Q24310863-A87EFD87-40F3-46A7-B677-404E8A1B6996 Q24681480-F502F680-904C-42F4-9B97-EDBD9EE8E643 Q24812104-2C2E998F-4AFE-4328-AF4C-35211D5021CC Q26746934-51559DD2-0FB8-4D1E-9348-95F719E1A46C Q26769594-6B9D0CE1-162D-445F-8C2C-99FFACC15952 Q26773803-BB1B6FF5-E847-475D-AE60-25B43AC1DA97 Q26851166-F164C399-C23E-464E-B98F-398A75D22321 Q26859274-E25666CE-2074-4B47-AE33-641F32260EC5 Q26995192-9D2D7F32-4855-4722-BD15-1510C0FBC634 Q27005897-BC472AFB-2E8C-4ACD-9868-00753E110236 Q27009469-E356962F-68AE-45A4-A765-6E3CF150212A Q27025241-EB6B2385-E81A-4376-A16E-3362FBC9B202 Q27335252-8C989330-F32E-430D-BA29-2F9789B240E9 Q27853165-CCA0BE5A-54D9-4D76-B0F9-BE81BA22E7CD Q28082536-FA4011D9-BB4B-4804-96D7-4287A6FA79ED Q28265589-45A035AD-C40C-4E63-A942-0117C103EADD Q28282479-4256E0DC-6F8C-41C4-8FD6-0A5DB922B954 Q28290352-D5CCB34A-255A-4191-BB69-B78113C4CB20 Q28385690-78020965-B424-476F-BA91-11BC4DB4DFA0 Q28395597-EE561D1A-F37F-425F-AEE9-3B8B144990CF Q28482418-D6FAFB14-CA80-4569-B7F3-885122477FC2 Q28484904-878D7C96-3E6C-40F8-A244-E32E9565F5FB Q28972517-D1918B30-2BF1-493C-A1AC-B64BE2180F20 Q30538453-273DAABA-DD20-4FE8-B0EE-82F573ADF7FD Q30541284-FFBB495B-5F02-4265-B784-D8170A09CA65 Q30886620-01DF5A01-394E-4708-A7F4-11DD717CB8B7 Q30931932-D4702E86-4ADB-41D3-8A47-76A552CC794B Q31135325-F0616D11-76CC-47BE-99A5-32211C820825 Q32945672-BCEE8AF5-27B3-4E6F-B7BE-1F660DFE9416 Q33238940-15204F2E-8B5B-4FDC-A1B1-116718E97F57 Q33249818-4A9F634C-2A8D-4823-B6A7-12F5B4B557EF Q33259445-E58687E0-D111-46EE-8F44-2C49AEAE5B86 Q33375694-8239249F-EA57-404E-BBF8-39E48AE57EEA Q33381498-F48CE387-8E7F-40E3-89E8-BBF1E7E75C16 Q33384180-0C702FD6-2C24-4B63-B48C-7827E8FCDEFE Q33385544-366CF6B9-FA7F-4196-B9A6-F28283FBCAF0 Q33385966-7E09B1D4-EFEC-4865-836D-593741009422 Q33390536-FF5F654B-3A03-4E5B-953B-CAD4F9BFF7D2

P2860

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.

http://www.wikidata.org/entity/Q35758280

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Phase I study of an oral histo ...... patients with advanced cancer.

@ast

Phase I study of an oral histo ...... patients with advanced cancer.

@en

type

label

Phase I study of an oral histo ...... patients with advanced cancer.

@ast

Phase I study of an oral histo ...... patients with advanced cancer.

@en

prefLabel

Phase I study of an oral histo ...... patients with advanced cancer.

@ast

Phase I study of an oral histo ...... patients with advanced cancer.

@en

P1433

Q35758280-DFDD2DF4-38FF-4F5A-9289-C1863FF144EB

P1476

Q35758280-9B443289-229A-441F-AFB9-154ED6AE0F84

P2093

Q35758280-0216C448-AF67-4524-8F07-02C268BB0957

Q35758280-2626F07C-1BE2-4D57-BBC8-DBAB867B46F2

Q35758280-2D3B8AEB-7C89-4354-9F92-7877CD1ABC5F

Q35758280-3B4B87FF-9783-49C1-993F-88185C6E76BE

Q35758280-4AAA6D2F-CDE8-4253-8506-89A84C4DDA2E

Q35758280-4DFC22D0-302B-4D8E-8B91-D51FA1E1FE26

Q35758280-5D01906D-4F42-4626-81F9-16AEC9B5EEF1

Q35758280-628BCFA5-3A82-48FA-87DE-D05881103C56

Q35758280-80327555-AC67-42D2-B432-3F6F086D6FAF

Q35758280-81E77258-170B-4323-8C73-493B4351D64C

P2860

Q35758280-0F25D1B0-B869-4C31-BA32-CA1F97F60F57

Q35758280-133A13DE-51D2-469D-BA13-690B7F0A82C1

Q35758280-14E50864-D57B-44E5-96EE-49A72C5B929D

Q35758280-2382D92A-F961-4B9B-B820-0004CD357EE1

Q35758280-2FB00667-DE8A-4F6F-92FD-73ECFF3B6E11

Q35758280-40ADC411-32D1-44A2-9A80-3E350D7892CB

Q35758280-5876E2E1-04E4-48AB-95ED-93F8E40EC91F

Q35758280-5984B41D-2350-4462-89C6-D8E81F628685

Q35758280-68583CFC-0F3E-461A-A997-DD10841A6A89

Q35758280-97111FBB-7800-461E-84C9-D22781BCB78B

P304

Q35758280-261A451F-4B79-4A4C-9C94-C613932C503B

P31

Q35758280-6559C72E-B7ED-4EC2-B5E2-F3FF76D45A07

P356

Q35758280-EE2F56AB-393C-4667-8C90-49C4A8631E6F

P407

Q35758280-D06E57CB-65A9-4095-91EB-BE89AC42AE51

P433

Q35758280-A2739603-64DD-47F9-90F0-DEC88F99F49E

P478

Q35758280-EE9E164C-840E-445C-B20F-DBAAEF384DBD

P577

Q35758280-3EF32017-F6A0-4167-8B37-6567EF2B60B6

P5875

Q35758280-FAF0B632-002F-43FD-A292-23D84F66B60B

P698

Q35758280-324F4394-061B-4751-8BA6-41F080CBB292

P932

Q35758280-B53C7B79-4734-443D-BDE3-2DCDF1DB967D

P356

JCO.2005.14.167

P1433

Journal of Clinical Oncology

P1476

Phase I study of an oral histo ...... patients with advanced cancer.

@en

P2093

Barbara MacGregore-Cortelli

http://www.w3.org/2001/XMLSchema#string

Elaina Chu

http://www.w3.org/2001/XMLSchema#string

Howard Scher

http://www.w3.org/2001/XMLSchema#string

J Paul Secrist

http://www.w3.org/2001/XMLSchema#string

Judy H Chiao

http://www.w3.org/2001/XMLSchema#string

Lawrence Schwartz

http://www.w3.org/2001/XMLSchema#string

Lee M Krug

http://www.w3.org/2001/XMLSchema#string

Mark Heaney

http://www.w3.org/2001/XMLSchema#string

Owen A O'Connor

http://www.w3.org/2001/XMLSchema#string

Paul A Marks

http://www.w3.org/2001/XMLSchema#string

P2860

The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: implications for a role of BCL6 in the down-regulation of apoptosis

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

The diversity of acetylated proteins.

Histone methylation in transcriptional control

Reporting results of cancer treatment

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer.

Regulating the regulators: lysine modifications make their mark.

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.

P304

3923-3931

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.14.167

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2005-05-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7843077

http://www.w3.org/2001/XMLSchema#string

P698

15897550

http://www.w3.org/2001/XMLSchema#string

P932

1855284

http://www.w3.org/2001/XMLSchema#string